about
Clinically significant drug-drug interactions involving opioid analgesics used for pain treatment in patients with cancer: a systematic reviewBarriers to and facilitators for implementing quality improvements in palliative care - results from a qualitative interview study in NorwayPrevalence of distressing symptoms in hospitalised patients on medical wards: A cross-sectional study.Funding models in palliative care: Lessons from international experience.A systematic review on the role of fish oil for the treatment of cachexia in advanced cancer: an EPCRC cachexia guidelines project.Use of opioid analgesics in the treatment of cancer pain: evidence-based recommendations from the EAPC.Modelling the landscape of palliative care for people with dementia: a European mixed methods studyA pan-European survey of research in end-of-life cancer care.Physical exercise for cancer patients with advanced disease: a randomized controlled trial.Palliative care in Norway: a national public health model.Symptom assessment in palliative care: a need for international collaboration.Pain assessment tools in palliative care: an urgent need for consensus.Assessment and classification of cancer breakthrough pain: a systematic literature review.Clinical priorities, barriers and solutions in end-of-life cancer care research across Europe. Report from a workshop.Studies comparing Numerical Rating Scales, Verbal Rating Scales, and Visual Analogue Scales for assessment of pain intensity in adults: a systematic literature review.Cardiopulmonary resuscitation in palliative care cancer patients.How are palliative care cancer populations characterized in randomized controlled trials? A literature review.The European Association for Palliative Care basic dataset to describe a palliative care cancer population: Results from an international Delphi process.How are patient populations characterized in studies investigating depression in advanced cancer? Results from a systematic literature review.Characteristics of the case mix, organisation and delivery in cancer palliative care: a challenge for good-quality research.Safety and effectiveness of palliative drug treatment in the last days of life - a systematic literature review.Drug utilization and medication costs at the end of life.Characteristics of breakthrough cancer pain and its influence on quality of life in an international cohort of patients with cancer.[The specialist field of palliative medicine].Computer-based symptom assessment is feasible in patients with advanced cancer: results from an international multicenter study, the EPCRC-CSA.Users' perceptions on digital visualization of neuropathic cancer-related pain.Predictive value of tumour cell proliferation in locally advanced breast cancer treated with neoadjuvant chemotherapy.Computer-based assessment of symptoms and mobility in palliative care: feasibility and challenges.Palliative care in colorectal surgery - are we prepared?Patients with advanced cancer and depression report a significantly higher symptom burden than non-depressed patients.Preferences for place of death if faced with advanced cancer: a population survey in England, Flanders, Germany, Italy, the Netherlands, Portugal and Spain.Prevalence of pain in hospitalised cancer patients in Norway: a national survey.To be involved or not to be involved: a survey of public preferences for self-involvement in decision-making involving mental capacity (competency) within Europe.Development and testing of a computerized pain body map in patients with advanced cancer.The Nordic Specialist Course in Palliative Medicine: evaluation and experiences from the first course 2003-2005.Influence of TP53 gene alterations and c-erbB-2 expression on the response to treatment with doxorubicin in locally advanced breast cancer.Advance care planning in life-threatening pulmonary disease: a focus group study.Integration of oncology and palliative care: a Lancet Oncology CommissionSymptomkartlegging i palliativ medisinCancer pain research: Time to reset the strategy and the agenda
P50
Q26781972-55E13532-E086-4B17-9602-64F5C41B8062Q27308989-31FDB947-0AEA-4180-903A-A05955981136Q33371130-2978B4B7-D48C-4D2E-98C9-DD8A58B6942EQ33605418-E1B8E2B5-29B8-42CF-B9BC-856EE525E412Q34210506-01E69281-2996-435D-A67C-51947658256BQ34251507-2F878743-3464-4F83-9F02-BB6D0CD6C721Q34929211-A67A2995-A788-49EB-BE6D-0AE28CD1E99AQ35571759-5E1FB94A-0968-4C41-80F7-07953F76002EQ35599837-E6C248B9-F994-4CF8-97A7-B3AB15CC9311Q36812015-74A87618-1CC8-4214-95CD-E1591B833054Q37238228-722CA121-DE53-457C-A5F9-1A9B6C3A5C25Q37272337-8B5650FA-927D-4986-9DE2-A81A832ECF8CQ37710813-30B810D0-6CBB-4DD7-8859-D3585CDE97D3Q37748032-A2C3DE3C-7387-4796-A106-93959B84D79FQ37881331-D1F97E3D-53F4-4F5B-A0DA-3B2D04B2622AQ38082988-1B1BE122-FEE6-48F4-9F55-D4A9693E44E0Q38135649-C54E114B-2005-45BF-AF9B-C02B1E00F7A0Q38185859-A272A97B-DF0F-4035-A581-22D48FF575D3Q38200398-82A61146-7A5C-4DB1-A847-70F30BC1A844Q38391865-DE7A5ABE-C169-402C-B5F7-4C5C09931C0FQ38627400-4B15D125-FA69-45F6-BB77-64890604A065Q38751597-02CB11E0-4F71-4122-B5B2-D6FE68DD5AC2Q39170820-986B5044-19C6-4056-BD65-A23F1AF3D30CQ39355863-1C9BF559-E116-4EBA-B818-4A3D620112AAQ39586205-DACF960C-7183-417D-B68D-0F1591587812Q40489836-3D1B510B-8B92-46B7-A8BE-D8633F996C84Q44443788-BD54960A-E370-4F4C-AF10-032C60BE252CQ44911937-571B56D4-B263-4C02-94A6-3035FE5FB412Q45416882-0489DD57-7EC4-4331-ACA0-4993A28564C5Q47216466-D3A4E528-A1AC-4132-9B78-A1D4EFEAA847Q47224982-B359D6D2-6ECC-4425-8E54-4058A1F1447AQ48636289-95D0A2A5-C0A1-4AE0-96DA-D9A16015ECFFQ50722211-9907301D-7CD9-4AFD-8D57-7737AA1FA422Q51224406-67F89E93-B0E8-455D-8D94-6C10057F5F57Q51957273-DBE5C41A-D6FE-4CCC-8BDE-58DEB5DE8C67Q52542729-32283D51-75E1-4272-9D4A-0CE7D10B2F58Q55120287-E1BF964A-C244-48E2-9776-72266A802B28Q57813747-7BF54FB8-0EC3-43CB-BF9A-7CA0E97D0D57Q60729540-B24ED89E-C496-44FA-B970-0113768461C0Q60729542-BCEDA142-A7A9-4728-AED6-D1DB9A5DC862
P50
description
Noors onderzoekster
@nl
hulumtuese
@sq
researcher
@en
հետազոտող
@hy
name
Dagny Faksvåg Haugen
@ast
Dagny Faksvåg Haugen
@en
Dagny Faksvåg Haugen
@es
Dagny Faksvåg Haugen
@nl
Dagny Faksvåg Haugen
@sl
type
label
Dagny Faksvåg Haugen
@ast
Dagny Faksvåg Haugen
@en
Dagny Faksvåg Haugen
@es
Dagny Faksvåg Haugen
@nl
Dagny Faksvåg Haugen
@sl
prefLabel
Dagny Faksvåg Haugen
@ast
Dagny Faksvåg Haugen
@en
Dagny Faksvåg Haugen
@es
Dagny Faksvåg Haugen
@nl
Dagny Faksvåg Haugen
@sl
P106
P21
P27
P31
P496
0000-0002-8592-4995
P569
2000-01-01T00:00:00Z